JP2021524256A5 - - Google Patents
Info
- Publication number
- JP2021524256A5 JP2021524256A5 JP2020565492A JP2020565492A JP2021524256A5 JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5 JP 2020565492 A JP2020565492 A JP 2020565492A JP 2020565492 A JP2020565492 A JP 2020565492A JP 2021524256 A5 JP2021524256 A5 JP 2021524256A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022697A JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ox40抗体及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/088101 | 2018-05-23 | ||
| CN2018088101 | 2018-05-23 | ||
| PCT/CN2019/088013 WO2019223733A1 (en) | 2018-05-23 | 2019-05-22 | Anti-ox40 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Division JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ox40抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524256A JP2021524256A (ja) | 2021-09-13 |
| JP2021524256A5 true JP2021524256A5 (cg-RX-API-DMAC7.html) | 2022-05-23 |
| JP7489922B2 JP7489922B2 (ja) | 2024-05-24 |
Family
ID=68615676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Active JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ox40抗体及び使用方法 |
| JP2024022697A Withdrawn JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ox40抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Withdrawn JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ox40抗体及び使用方法 |
Country Status (14)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566935B (zh) * | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| WO2021098769A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| CA3157319A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
| WO2021098750A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| KR20220103709A (ko) * | 2019-11-21 | 2022-07-22 | 베이진 엘티디 | 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법 |
| EP4061850A4 (en) * | 2019-11-21 | 2024-03-20 | BeiGene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies |
| EP4136116A4 (en) | 2020-04-17 | 2024-06-19 | Hutchison Medipharma Limited | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技(北京)有限公司 | 结合ox40的抗体或抗原结合片段 |
| CN118488965A (zh) | 2021-12-17 | 2024-08-13 | 上海复宏汉霖生物技术股份有限公司 | 抗ox40抗体、多特异性抗体及其使用方法 |
| AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| WO2024141049A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗ox40抗体及其应用 |
| WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
| WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
| TW202436345A (zh) | 2023-03-06 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | 抗cd3多特異性抗體及使用方法 |
| IL324457A (en) | 2023-05-12 | 2026-01-01 | Genmab As | Antibodies capable of binding to ox40, their variants and uses thereof |
| WO2024240247A1 (en) * | 2023-05-25 | 2024-11-28 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies |
| CN122249464A (zh) | 2023-11-30 | 2026-06-19 | 金麦安博股份有限公司 | 在组合疗法中的能够结合ox40的抗体 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| MX2009005189A (es) | 2006-11-15 | 2009-06-30 | Medarex Inc | Anticuerpos humanos monoclonales para btla y metodos de uso. |
| EP2183254B1 (en) | 2007-08-29 | 2017-06-21 | MethylGene Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2009126688A2 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| PL2552961T3 (pl) * | 2010-03-30 | 2018-04-30 | Janssen Biotech, Inc. | Humanizowane przeciwciała il-25 |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| LT2609118T (lt) * | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| CN102010407A (zh) | 2010-11-16 | 2011-04-13 | 上海科胜药物研发有限公司 | 一种合成达沙替尼的新方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| RS57840B1 (sr) * | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| TWI726608B (zh) * | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
| CA2963974A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| CN106999583A (zh) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| PL3265123T3 (pl) * | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| JP6815329B2 (ja) | 2015-03-23 | 2021-01-20 | バイエル ファーマ アクチエンゲゼルシャフト | 抗ceacam6抗体およびその使用 |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| AU2016274585A1 (en) | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
| WO2017063162A1 (zh) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| US10781260B2 (en) | 2016-08-08 | 2020-09-22 | Sorrento Therapeutics, Inc. | Anti-OX40 binding proteins |
| MX2019002242A (es) | 2016-08-26 | 2019-08-16 | Beigene Ltd | Anticuerpos anti-tim-3 y uso de los mismos. |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CA3084394A1 (en) | 2017-11-24 | 2019-05-31 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ox40 antibodies and uses thereof |
| CN110092832B (zh) | 2018-01-29 | 2020-03-31 | 康源博创生物科技(北京)有限公司 | 抗ox40抗体及其用途 |
| CN110467674B (zh) | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| CN112566935B (zh) * | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| EP4061850A4 (en) | 2019-11-21 | 2024-03-20 | BeiGene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies |
| WO2021098769A1 (en) | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| WO2021098750A1 (en) | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| CA3157319A1 (en) | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
| US20230011916A1 (en) | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| KR20220103709A (ko) | 2019-11-21 | 2022-07-22 | 베이진 엘티디 | 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법 |
-
2019
- 2019-05-22 CN CN201980034638.8A patent/CN112566935B/zh active Active
- 2019-05-22 KR KR1020207035920A patent/KR20210013708A/ko active Pending
- 2019-05-22 AU AU2019272384A patent/AU2019272384A1/en not_active Abandoned
- 2019-05-22 WO PCT/CN2019/088013 patent/WO2019223733A1/en not_active Ceased
- 2019-05-22 MX MX2020012567A patent/MX2020012567A/es unknown
- 2019-05-22 SG SG11202011024WA patent/SG11202011024WA/en unknown
- 2019-05-22 EP EP19806419.8A patent/EP3797123A4/en active Pending
- 2019-05-22 US US17/055,267 patent/US12103974B2/en active Active
- 2019-05-22 BR BR112020023746-9A patent/BR112020023746A2/pt not_active IP Right Cessation
- 2019-05-22 EA EA202092460A patent/EA202092460A1/ru unknown
- 2019-05-22 JP JP2020565492A patent/JP7489922B2/ja active Active
- 2019-05-23 TW TW108117808A patent/TW202016133A/zh unknown
-
2020
- 2020-11-06 ZA ZA2020/06931A patent/ZA202006931B/en unknown
- 2020-11-17 IL IL278772A patent/IL278772A/en unknown
- 2020-11-23 MX MX2024013960A patent/MX2024013960A/es unknown
-
2024
- 2024-02-19 JP JP2024022697A patent/JP2024056938A/ja not_active Withdrawn
- 2024-08-28 US US18/818,381 patent/US20240409655A1/en active Pending